New ALK-Positive Lung Cancer Grant Seeks Innovative Research Approaches

The Lung Cancer Research Foundation (LCRF) is paving the way for remarkable advancements in lung cancer treatment with the announcement of a new research grant. Open for proposals, this two-year, $300,000 research award aims to enhance treatment options for individuals suffering from anaplastic lymphoma kinase (ALK) fusion-driven non-small cell lung cancer (NSCLC). This grant opportunity is not just a financial boost; it represents hope for new investigative pathways that could lead to significant breakthroughs in patient care.

The journey to this pivotal grant began in 2007 when researchers identified a specific genetic abnormality known as EML4-ALK that significantly contributes to a subset of lung cancers. This discovery catalyzed the development of targeted therapies, specifically ALK inhibitors. The initial FDA approval for these inhibitors came in 2011, marking a crucial turning point in the management of ALK-positive NSCLC.

The latest innovation in this category, lorlatinib, is noteworthy for its ability to counteract resistance commonly seen with earlier drugs. A comprehensive clinical trial known as CROWN demonstrated that lorlatinib offers longer progression-free survival compared to its predecessor, crizotinib, compellingly showcasing its efficacy in managing brain metastases. Recent follow-ups from this trial have reported remarkably positive outcomes, with over half of the participants showing stable disease after seven years of treatment, the best results ever documented for a singular targeted therapy in advanced nonsmall cell lung cancer.

Despite these advancements, challenges remain. Even the most effective therapies inevitably face the challenge of resistance—with standard options like chemotherapy and clinical trials being the only recourse when these therapies cease to be effective. This underscores the urgent need for continued funding and innovative research efforts, like those offered through the LCRF grant, to address the evolving nature of ALK-positive tumors. The mission is clear: understanding the underlying mechanisms that contribute to tumor growth, treatment responses, and the development of resistance is crucial.

The 2026 LCRF Award is keenly focused on understanding the science of ALK alterations as drivers of malignancy, fostering the creation of novel therapeutic techniques. Researchers are encouraged to devise proposals that include translational research, which will enrich our understanding of ALK-driven cancers, potentially leading to remarkable advances in patient survival rates.

Bruce Dunbar, a member of the LCRF Board of Directors and a survivor of ALK-positive lung cancer, expressed the importance of such grants, stating, "Grants like this are critical to ensuring there are more options and new approaches to treating ALK-positive NSCLC that has stopped responding to existing therapies. More investment in research means more ALK patients will live longer and better lives and the closer we'll get to a cure."

Kathryn A. O'Donnell, PhD, affiliated with the UT Southwestern Medical Center and Chair of the Scientific Advisory Board of LCRF, highlighted the pressing need for continuous research funding. She emphasized, "Science has already given many people with ALK-positive lung cancer years they wouldn't otherwise have had. But we cannot stop there. Resistance will eventually develop, and we have an obligation to be ready. Funding this research now is how we make sure the next breakthrough will happen."

This substantial grant has been made possible through the contributions of various stakeholders in the lung cancer community, including individual donors, family foundations, and corporate sponsorship. The collaborative effort fuels the mission to identify and nurture innovative research that could change the landscape of lung cancer treatment.

Potential applicants for this grant will undergo a rigorous review process comprising a two-step evaluation: Letters of Intent are due on July 15, 2026, and selected candidates will be invited to submit full proposals for further scrutiny by LCRF's Scientific Advisory Board. Detailed information about the Request for Proposal, along with eligibility criteria and application deadlines, can be found at LCRF.org/FundingOpportunities.

The LCRF stands as a beacon of hope in the fight against lung cancer, having funded over 450 research grants totaling nearly $53 million to date, more than any other nonprofit organization dedicated to this cause. Their unwavering commitment to improving patient outcomes through innovative research demonstrates the potential for change and advancement in the field.

For more information about the Lung Cancer Research Foundation, visit their website at lcrf.org.